Postremission therapy in adult acute myeloid leukemia (AML): A randomized comparison between high dose ara-C therapy and conventional consolidation therapy (JALSG AML 201 study).

被引：0

作者：

Miyawaki, Shuichi ^{[1
]}

Ohtake, Shigeki ^{[1
]}

Fujisawa, Shin ^{[1
]}

Kiyoi, Hitoshi ^{[1
]}

Shinagawa, Katsuji ^{[1
]}

Usui, Noriko ^{[1
]}

Miyamura, Koichi ^{[1
]}

Nishimura, Miki ^{[1
]}

Miyazaki, Yasushi ^{[1
]}

Nishii, Kazuhiro ^{[1
]}

Nagai, Tadashi ^{[1
]}

Yamane, Takahisa ^{[1
]}

Taniwaki, Masafumi ^{[1
]}

Takahashi, Masatomo ^{[1
]}

Yagasaki, Fumiharu ^{[1
]}

Kimura, Yukihiko ^{[1
]}

Asou, Norio ^{[1
]}

Honda, Sumihisa ^{[1
]}

Ohnishi, Kazunori ^{[1
]}

Naoe, Tomoki ^{[1
]}

Ohno, Ryuzo ^{[1
]}

机构：

[1] Saiseikai Maebashi Hosp, Leukaemia Res Ctr, Maebashi, Gumma, Japan

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

10.1182/blood.V108.11.2005.2005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2005

引用

页码：567A / 567A

页数：1

共 50 条

[31] Comparison of the cyclophosphailiide (C), ara-c (A), topotecan (T), (CAT) regimen to ara-c plus topotecan or idarubicin (I) as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia (AML).
Beran, H
Giles, FJ
Cortes, JE
Thomas, DA
Koller, C
O'Brien, SM
Keating, MJ
Freireich, E
Kantarjian, HM
Estey, E
BLOOD, 1999, 94 (10) : 226B - 226B
[32] A phase I study of busulfan consolidation/intensification therapy for patients with high risk acute myeloid leukemia (AML).
Gharibo, M. M.
Schaar, D.
Rubin, A.
Grospe, S.
Dudek, L.
Strair, R.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
[33] Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Dombret, Herve
Preudhomme, Claude
Boissel, Nicolas
CURRENT OPINION IN HEMATOLOGY, 2009, 16 (02) : 92 - 97
[34] Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia (AML).
Case, DC
Ebrahim, KS
Aronson, FR
Hedlund, JA
BLOOD, 2000, 96 (11) : 209B - 209B
[35] Follow-up Analysis of a Randomized Comparison of Prolonged Myelosuppressive Maintenance Therapy Versus Intensive Consolidation Therapy as Postremission Therapy in AML.
Krug, Utz O.
Sauerland, Maria Cristina
Woermann, Bernhard J.
Berdel, Wolfgang
Hiddemann, Wolfgang
Buchner, Thomas
BLOOD, 2009, 114 (22) : 437 - 437
[36] ARA-C AND AMSA IN THE THERAPY OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA
JAGER, U
WIENER KLINISCHE WOCHENSCHRIFT, 1986, 98 (17) : 589 - 589
[37] Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML)
Faderl, S
Ravandi, F
Ferrajoli, A
Garcia-Manero, G
Estrov, Z
Thomas, DA
O'Brien, S
Verstovsek, S
Wierda, W
Cortes, J
Giles, FJ
Kwari, M
Jarmon, R
Kantarjian, HM
BLOOD, 2005, 106 (11) : 786A - 786A
[38] ACUTE CEREBELLAR DYSFUNCTION WITH HIGH-DOSE ARA-C THERAPY
SALINSKY, MC
LEVINE, RL
AUBUCHON, JP
SCHUTTA, HS
CANCER, 1983, 51 (03) : 426 - 429
[39] Randomized clinical trial of induction therapy comparing intensified daunorubicin with idarubicin in patients with previously untreated de novo acute myeloid leukemia (JALSG AML201 study).
Ohtake, Shigeki
Miyawaki, Shuichi
Fujita, Hiroyuki
Kiyoi, Hitoshi
Shinagawa, Katsuji
Usui, Noriko
Miyamura, Koichi
Nishimura, Miki
Miyazaki, Yasushi
Nishii, Kazuhiro
Nagai, Tadashi
Yamane, Takahisa
Taniwaki, Masafumi
Takahashi, Masatomo
Yagasaki, Fumiharu
Kimura, Yukihiko
Asou, Norio
Honda, Sumihisa
Ohnishi, Kazumori
Naoe, Tomoki
Ohno, Ryuzo
BLOOD, 2006, 108 (11) : 566A - 566A
[40] INTERMEDIATE-DOSE ARA-C M-AMSA FOR REMISSION INDUCTION AND HIGH-DOSE ARA-C M-AMSA FOR INTENSIVE CONSOLIDATION IN RELAPSED AND REFRACTORY ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
JEHN, U
HEINEMANN, V
WILMANNS, W
ANTICANCER RESEARCH, 1989, 9 (01) : 119 - 124

← 1 2 3 4 5 →